Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-04-06
DOI
https://doi.org/10.1080/14796694.2026.2648863
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study

S. Jung, Thomas E. Stinchcombe, Eziafa Oduah, T. Zhang et al.
Future Oncology
Cancer Immunotherapy and Biomarkers
article

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study

S. Jung, Thomas E. Stinchcombe, Eziafa Oduah, T. Zhang, Neal Ready, Jeffrey M. Clarke, Jhanelle E. Gray, Jeffrey Crawford, Scott J. Antonia
article en

Abstract

No abstract available for this paper.
Future OncologyVol. 22(9)
Duke University (US), Moffitt Cancer Center (US), Parker Institute for Cancer Immunotherapy (US)
Regeneron Pharmaceuticals
Good health and well-being
Openalex Percentile: Top 23%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.